Recruiting

Tri-layer Amnion Graft & Single Layer Amnion Graft

Sponsor:

Capsicure, LLC

Code:

NCT07046767

Conditions

Diabetic Foot Ulcer (DFU)

Venous Leg Ulcer

Wound; Foot

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap

IP2: BioLab Tri-Membrane Wrap

Study Details

Brief summary:

CAMP RWE Trial: A Multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri-layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

Conditions

Diabetic Foot Ulcer (DFU)

Venous Leg Ulcer

Wound; Foot

Study ID

NCT07046767

Start date

Oct 1, 2025

Status verified date

Oct, 2025

Completion date

Jul 20, 2026

Anticipated

Primary completion date

Jul 20, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female 18 years of age and older
2. 2\. Subjects having a non-healing venous leg ulcer or diabetic foot ulcer of >4 weeks duration and visible signs of healing objectively, less than 50% reduction in wound size in the last 4 weeks
3. Subjects' wound size is minimum of 2 cm2 and maximum of 25cm2
4. If the subject has more than one eligible wound the largest wound will be selected (the index wound)
5. Subject is able and willing to follow the protocol requirements
6. Subject has signed informed consent

Exclusion Criteria:

1. Inability to adhere to the study protocol or study visit schedule
2. Pregnancy
3. Child-bearing potential without appropriate contraception
4. Lactation
5. Treatment of the wound with engineered tissue or other scaffold materials within 30 days preceding the first treatment visit.
6. Visible signs of improvement in the four weeks before randomisation (defined objectively as a 50% reduction in surface area in the four weeks before enrolment)
7. The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety
8. Known contraindications to the use of amniotic tissue grafts
9. The index ulcer shows clinical signs and symptoms of wound infection needing treatment with local or systemic antimicrobials or antibiotics

Study Design

Enrollment

165 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

no intervention: Standard of Care

This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group.

Subjects will be randomized to one of two interventions:

IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap

Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)

experimental: IP1: BioLab Membrane Wrap Lite

This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group.

Subjects will be randomized to one of two interventions:

IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap

Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)

experimental: IP2: BioLab Tri-Membrane Wrap

This study will employ a platform umbrella design in which two studies will be run: one for diabetic foot ulcers and one for venous leg ulcers. Each study will have two intervention groups and one common SOC group.

Subjects will be randomized to one of two interventions:

IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap

Subjects in the control group will be drawn from deidentified data sourced from the US Wound Registry. The US Wound Registry (USWR) is recognized by CMS as a Qualified Clinical Data Registry (QCDR). The matching of intervention to control groups will use coarsened exact matching (CSM) in which key variables are used to match: e.g., age, sex, baseline wound area, baseline wound age. The desired control subject pool should be three times larger than the prospective group (at least 165 in wound type.)

Interventions

IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap

BioLab Membrane Wrap LiteTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Membrane Wrap LiteTM is a single-layer human tissue allograft, containing solely the amnion layer of Amniotic Membrane \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.

IP2: BioLab Tri-Membrane Wrap

BioLab Tri-Membrane WrapTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Tri-Membrane WrapTM is a triple-layered human tissue allograft, containing amnion-chorion-amnion layers \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.

Primary outcome measure

  • Wound Closure [ Time Frame: 12 Weeks ]

Central Contacts and Locations

Central contacts

Marissa Docter, RN, BSN, MD

512-571-2966mdocter@capsicure.com

Locations

FOMAT Medical Research

Recruiting

Oxnard, California, United States, 93030

Contacts

Principal Investigator:

David Blitzer, MD

Solutions Medical Research

Recruiting

Coral Gables, Florida, United States, 33134

Contacts

Principal Investigator:

Francisco Jose Oliva, DPM

Nova Medical Services - Research Division LLC

Recruiting

Miami, Florida, United States, 33176

Contacts

Principal Investigator:

Sandor Romero, MD

Indiana University Health Methodist Hospital

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Principal Investigator:

Mithun Sinha, PhD

St. Louis Foot and Ankle, LLC

Recruiting

St Louis, Missouri, United States, 63128

Contacts

Principal Investigator:

Raymond Abdo, DPM

Jevlos Health, Inc

Recruiting

Syosset, New York, United States, 11791

Contacts

Principal Investigator:

Mamta Parikh, MD

Hope Vascular and Podiatry

Recruiting

Houston, Texas, United States, 77054

Contacts

Principal Investigator:

Brian Lepow, DPM

More Information

Sponsor

Capsicure, LLC

Last update posted

Oct 22, 2025

Last verified

Oct, 2025

Keywords

  • DCF
  • VLU
  • Diabetic Foot Ulcer
  • Venus Leg Ulcer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Capsicure, LLC on 2025-10-22.